The worst news of all for investors, though, is that Medtronic stock costs a rich 25 times trailing earnings today, and ...

Medtronic (NYSE: MDT) PLC rapporteerde haar eerste kwartaalcijfers voor het fiscale jaar 2026, waarbij de verwachtingen van Wall Street werden overtroffen met een aangepaste winst per aandeel (EPS) va ...

Goldman Sachs merkte op dat beleggers hadden gerekend op een versnelling van de totale organische groei na sterke prestaties in cardiale ablatieoplossingen, maar de resultaten benadrukten hoe ...

Medtronic (MDT) stock in focus as the company raises FY2025 earnings outlook amid Q1 outperformance and reduced tariff impact ...

FQ1 results and guidance update did not spark a rally in the share price. Still, they did affirm a robust outlook that ...

Medtronic reported strong first-quarter 2026 results, with sales hitting $8.58 billion, surpassing the consensus estimate of ...

Medtronic (MDT) recently reported its Q1 FY2026 earnings, showing an increase in sales to $8,578 million, while net income ...

Medtronic develops and manufactures a wide range of medical devices, including implantable cardiac pacemakers, heart valves, neurostimulation systems, insulin pumps, and surgical robotics platforms.

Q1 2026 Earnings Call Transcript August 19, 2025 Medtronic plc beats earnings expectations. Reported EPS is $1.26, ...

Elliott Partner Marc Steinberg stated that the decision to become one of the largest investors in Medtronic was driven by the ...

Medtronic PLC (MDT) reports robust growth across key segments, raises full-year EPS guidance, and outlines strategic ...

The medical device company posted revenue of $8.58 billion in the period, also beating Street forecasts. Eleven analysts surveyed by Zacks expected $8.37 billion. Medtronic expects full-year earnings ...